Biosimilar Market in Europe Share, Industry Analysis, and Report 2024-2032

Biosimilar Market in Europe 2024

Base Year: 2023

Historical Years: 2018-2023

Forecast Years: 2024-2032

Market Size in 2023: US$ 11,849.5 Million

Market Forecast in 2032: US$ 53,222.9 Million

Market Growth Rate: 17.6% (2024-2032)

How Big is the Biosimilar Industry in Europe?

The biosimilar market in Europe size reached US$ 11,849.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 53,222.9 Million by 2032, exhibiting a growth rate (CAGR) of 17.6% during 2024-2032.

For an in-depth analysis, you can refer free sample copy of the report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample

Biosimilar Market in Europe Trends:

Demand and Market Dynamics

  • Escalating demand for cost-effective biologic therapies
  • Patent expirations of several blockbuster biologics opening avenues for biosimilar manufacturers
  • Increased competition leading to competitive pricing

Health and Disease Factors

  • Rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders
  • Growing need for affordable treatment options, bolstering biosimilar uptake

Healthcare Provider and Payer Influence

  • Recognition of economic benefits by healthcare providers and payers
  • Broader acceptance and integration into treatment protocols

Awareness and Education

  • Increased awareness among patients and healthcare professionals about biosimilars' safety and efficacy
  • Government and private sector initiatives promoting biosimilars through reimbursement policies and educational campaigns

Technological Advancements

  • Advancements in biotechnological processes and manufacturing efficiencies enabling high-quality biosimilar production and market penetration

Biosimilar Market in Europe Scope and Growth Analysis:

Broadening Scope of the Biosimilar Market

  • Personalized Medicine: Increasing focus on personalized medicine highlights the need for diverse biosimilar products tailored to specific patient needs.
  • Expanding Healthcare Infrastructure: Growth in healthcare infrastructure across Europe, especially in emerging economies, provides fertile ground for biosimilar market expansion.
  • Strategic Collaborations: Partnerships among pharmaceutical companies are facilitating the development and commercialization of a robust biosimilar pipeline.
  • Supportive Regulatory Landscape: Streamlined approval processes and post-marketing surveillance enhance market credibility and growth prospects.

Driving Innovation and Efficiency

  • Advanced Technologies: Integration of next-generation sequencing and bioinformatics in biosimilar development propels innovation and efficiency.
  • Research and Development Investments: Increasing investments by public and private entities foster the discovery of novel biosimilar candidates.
  • Competitive Pricing: Competitive pricing of biosimilars compared to reference biologics makes them an attractive option for budget-constrained healthcare systems, widening their market reach.

Ask Analyst For Customization: https://www.imarcgroup.com/request?type=report&id=1023&flag=C

By the IMARC Group, the Top Competitive Landscapes Operating in the Industry:

  • Novartis
  • Pfizer
  • Teva 
  • Celltrion 
  • Merck Sharp & Dohme
  • Samsung Bioepis 
  • Eli Lilly
  • Accord Healthcare Ltd.
  • Amgen
  • Boehringer Ingelheim
  • Hexal Ag 
  • Apotex 
  • Stada Arzneimittel Ag
  • Ratiopharm
  • Mylan

Biosimilar Market in Europe Market Research and Segmentation:

The report has segmented the market into the following categories:

Breakup by Molecule:

  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa
  • Adalimumab

Breakup by Indication:

  • Auto-Immune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility

Breakup by Manufacturing Type:

  • In-house Manufacturing
  • Contract Manufacturing

Breakup by Country:

  • Italy
  • Germany
  • United Kingdom
  • France
  • Spain
  • Rest of Europe

Key highlights of the Report:

  • Market Performance (2018-2023)
  • Market Outlook (2024-2032)
  • COVID-19 Impact on the Market
  • Porter’s Five Forces Analysis
  • Strategic Recommendations
  • Historical, Current and Future Market Trends
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Structure of the Market
  • Value Chain Analysis
  • Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: [email protected] 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145